Trial Information
Summary: A Phase II Evaluation of Docetaxel and Gemcitabine + G-CSF in the Treatment of Recurrent or Persistent Leimyosarcoma of the Uterus
This research study is for women who have been diagnosed with
uterine cancer, specifically leiomyosarcoma, that has come back or
continues to grow after initial standard surgery and chemotherapy.
The purpose of this study is to compare the effectiveness and
safety of treating cancer of the uterus using a combination of two
chemotherapy drugs: docetaxel and gemcitabine. Study participants
will receive both docetaxel and gemcitabine.
No Compensation Provided
Patient Inclusion/Exclusion Criteria:
You may be eligible to participate if you
-are 18 years of age or older
-have recurrent or persistent leiomyosarcoma of the uterus which is
resistant to surgery and chemotherapy
-meet additional criteria
You cannot participate in this study if you
-are pregnant or breastfeeding
-have had prior therapy with docetaxel or gemcitabine
|
Contact:
Rudy Segna, MD, Prinicpal Investigator
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Telephone: 212-888-8439
Fax: 212-319-1140
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 5:45:36 AM